NCT07624305ClinicalTrials.gov
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)
باختصار
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered…
المرحلة 3مطلوب 2,800 مشارك478 موقعاً27 دولة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07624305فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل شهرين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-06-03; recorded start 2026-09-01
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 45 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 2,800 participants (target), run at 478 sites, across 27 countries.
How this score is built
- Enrolment34/40
2,800 participants (target)
- Site count19/25
45 sites
- Country count12/15
8 countries
- Planned duration9/10
Planned over about 47 months
- Sponsor scale10/10
AstraZeneca has led 999 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.
الحالات
- Renal Insufficiency, Chronic
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – 99 Years |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 2,800 مشارك |
الجهة الراعية والمتعاونون
- AstraZeneca الجهة الراعية
الأذرع والتدخلات
- Balcinrenone/dapagliflozinEXPERIMENTAL
Patient receives once daily 1 capsule balcinrenone 15 mg and dapagliflozin 10 mg and 1 placebo tablet matching dapagliflozin.
- DapagliflozinACTIVE_COMPARATOR
Patient receives once daily 1 placebo capsule matching balcinrenone and dapagliflozin and 1 tablet dapagliflozin 10 mg.
التدخلات
- دواء Balcinrenone/dapagliflozin
balcinrenone/dapagliflozin 15 mg/10 mg
- دواء Dapagliflozin
dapagliflozin 10 mg
- دواء Placebo matching Dapagliflozin
matching placebo for dapagliflozin 10 mg
- دواء Placebo matching balcinrenone/dapagliflozin
matching placebo for balcinrenone/dapagliflozin
مقاييس النتائج
مقياس النتيجة الأولي
Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event
Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure * Initiation of maintenance dialysis or * Kidney transplantation * Sustained ≥ 50% decline from baseline in eGFR * HF with or without hospitalisation
الإطار الزمني Up to 46 months.
مقياس النتيجة الثانوي
Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure and sustained 50% or greater decline in eGFR.
Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure: * Initiation of maintenance dialysis or * Kidney transplantation Sustained ≥ 50% decline from baseline in eGFR
الإطار الزمني Up to 46 months.
مقياس النتيجة الثانوي
Change in urinary albumin to creatinine ratio to Week 24
Change from baseline to Week 24 in urinary albumin to creatinine ratio
الإطار الزمني Baseline to Week 24
مقياس النتيجة الثانوي
Time to first occurrence of cardiovascular death or heart failure event.
Time from randomization to first occurrence of any of the components of the composite: * CV death * HF with or without hospitalisation
الإطار الزمني Up to 46 months.
مقياس النتيجة الثانوي
Time to cardiovascular death
Time from randomization to cardiovascular death.
الإطار الزمني Up to 46 months.
مقياس النتيجة الثانوي
Time to death from any cause
Time from randomization to death from any cause.
الإطار الزمني Up to 46 months.
التواريخ
| تاريخ البدء | 1 سبتمبر 2026 (فعلي) |
|---|---|
| الإتمام الأولي | 1 يوليو 2030 (تقديري) |
| الإتمام | 1 يوليو 2030 (تقديري) |
| أول نشر | 3 يونيو 2026 (فعلي) |
| آخر تحديث | 24 سبتمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | سبتمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
33 موقعاً قيد التجنيد
Argentina
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Research Site | CABA | لم يبدأ التجنيد بعد | |
| Research Site | Capital Federal | لم يبدأ التجنيد بعد | |
| Research Site | Ciudad de Buenos Aires | لم يبدأ التجنيد بعد | |
| Research Site | La Plata | لم يبدأ التجنيد بعد | |
| Research Site | Lanús Este | لم يبدأ التجنيد بعد | |
| Research Site | Mar del Plata | لم يبدأ التجنيد بعد | |
| Research Site | Rosario | لم يبدأ التجنيد بعد | |
| Research Site | Rosario | لم يبدأ التجنيد بعد | |
| Research Site | Rosario | لم يبدأ التجنيد بعد | |
| Research Site | San Nicolás | لم يبدأ التجنيد بعد | |
| Research Site | Santa Fe | لم يبدأ التجنيد بعد | |
| Research Site | Santa Fe | لم يبدأ التجنيد بعد |
Austria
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Research Site | Feldkirch | لم يبدأ التجنيد بعد | |
| Research Site | Innsbruck | لم يبدأ التجنيد بعد | |
| Research Site | Linz | لم يبدأ التجنيد بعد | |
| Research Site | Sankt Pölten | لم يبدأ التجنيد بعد | |
| Research Site | Vienna | لم يبدأ التجنيد بعد | |
| Research Site | Vienna | لم يبدأ التجنيد بعد | |
| Research Site | Vienna | لم يبدأ التجنيد بعد | |
| Research Site | Vienna | لم يبدأ التجنيد بعد | |
| Research Site | Wels | لم يبدأ التجنيد بعد | |
| Research Site | Wiener Neustadt | لم يبدأ التجنيد بعد |
Brazil
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Research Site | Barretos | لم يبدأ التجنيد بعد | |
| Research Site | Belo Horizonte | لم يبدأ التجنيد بعد | |
| Research Site | Belo Horizonte | لم يبدأ التجنيد بعد | |
| Research Site | Belém | لم يبدأ التجنيد بعد | |
| Research Site | Campinas | لم يبدأ التجنيد بعد | |
| Research Site | Goiânia | لم يبدأ التجنيد بعد | |
| Research Site | Natal | لم يبدأ التجنيد بعد | |
| Research Site | Recife | لم يبدأ التجنيد بعد | |
| Research Site | São Caetano do Sul | لم يبدأ التجنيد بعد | |
| Research Site | São José do Rio Preto | لم يبدأ التجنيد بعد | |
| Research Site | São José dos Campos | لم يبدأ التجنيد بعد | |
| Research Site | São Paulo | لم يبدأ التجنيد بعد | |
| Research Site | São Paulo | لم يبدأ التجنيد بعد | |
| Research Site | São Paulo | لم يبدأ التجنيد بعد | |
| Research Site | São Paulo | لم يبدأ التجنيد بعد |
Bulgaria
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Research Site | Blagoevgrad | لم يبدأ التجنيد بعد | |
| Research Site | Nova Zagora | لم يبدأ التجنيد بعد | |
| Research Site | Pleven | لم يبدأ التجنيد بعد | |
| Research Site | Plovdiv | لم يبدأ التجنيد بعد | |
| Research Site | Sandanski | لم يبدأ التجنيد بعد | |
| Research Site | Sevlievo | لم يبدأ التجنيد بعد | |
| Research Site | Sofia | لم يبدأ التجنيد بعد | |
| Research Site | Sofia | لم يبدأ التجنيد بعد | |
| Research Site | Sofia | لم يبدأ التجنيد بعد | |
| Research Site | Stara Zagora | لم يبدأ التجنيد بعد | |
| Research Site | Varna | لم يبدأ التجنيد بعد |
Canada
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Research Site | Brampton | Ontario | لم يبدأ التجنيد بعد |
| Research Site | Calgary | Alberta | مسحوب |
يُدرَج 428 موقعاً إضافياً في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 24 سبتمبر 2026
تغيّرت الحالة
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 24 سبتمبر 2026
فُتح التجنيد
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 24 سبتمبر 2026
أُضيف موقع
433 sites added (478 total)
45478